LYMPHOPLASMACYTIC LYMPHOMA
Clinical trials for LYMPHOPLASMACYTIC LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new LYMPHOPLASMACYTIC LYMPHOMA trials appear
Sign up with your email to follow new studies for LYMPHOPLASMACYTIC LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cancer vaccine trial tests immune system boost for rare lymphoma
Disease control CompletedThis phase 1 trial tested a personalized DNA vaccine in 9 patients with a rare, slow-growing blood cancer called lymphoplasmacytic lymphoma. The vaccine was made from each patient's own cancer cells and designed to help the immune system recognize and attack the cancer. The main …
Matched conditions: LYMPHOPLASMACYTIC LYMPHOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Early trial explores new drug for blood cancers in japanese patients
Disease control CompletedThis early-phase study tested a new drug called nemtabrutinib in 7 Japanese adults with certain blood cancers (like chronic lymphocytic leukemia). The main goals were to check the drug's safety and how the body processes it. Researchers looked for side effects and measured drug l…
Matched conditions: LYMPHOPLASMACYTIC LYMPHOMA
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Half-Matched stem cell transplant shows promise for older blood cancer patients
Disease control CompletedThis study tested a stem cell transplant from half-matched (haploidentical) family donors for 34 people with various blood cancers. Patients received a reduced-intensity conditioning regimen of fludarabine, melphalan, and total body irradiation before the transplant. The goal was…
Matched conditions: LYMPHOPLASMACYTIC LYMPHOMA
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
CAR-T therapy Follow-Up study shows no new safety surprises
Knowledge-focused CompletedThis study followed 16 people who had already received a special immune cell treatment (CLBR001 CAR-T) for various types of B-cell blood cancers like lymphoma and leukemia. The goal was to check for any new or long-term side effects that might appear months or years after treatme…
Matched conditions: LYMPHOPLASMACYTIC LYMPHOMA
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC